Alnuctamab
drugOn this page
Summary
Alnuctamab (CHEMBL6068570) is a phase-3 clinical-stage antibody; indicated across 1 condition including plasma cell myeloma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 1 condition
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6068570 |
| Name | Alnuctamab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Alnuctamab, ALNUCTAMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| plasma cell myeloma | 3 | MONDO:0009693 | EFO:0001378 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06232707 | PHASE3 | WITHDRAWN | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) |
| NCT06121843 | PHASE1 | RECRUITING | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma |
| NCT07219563 | PHASE1 | RECRUITING | Alnuctamab for Refractory SLE (LATTE Study) |
| NCT06163898 | PHASE1 | TERMINATED | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: plasma cell myeloma